deltatrials
Completed PHASE4 INTERVENTIONAL 2-arm NCT02957682

Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Praluent on Neurocognitive Function in Patients With Heterozygous Familial Hypercholesterolemia or With Non-Familial Hypercholesterolemia at High and Very High Cardiovascular Risk

Sponsor: Regeneron Pharmaceuticals

Conditions Hypercholesterolemia
Interventions Placebo Praluent (Alirocumab)
Updated 19 times since 2017 Last updated: Apr 14, 2021 Started: Nov 2, 2016 Primary completion: Mar 5, 2020 Completion: Mar 5, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Hypercholesterolemia and is currently completed. Regeneron Pharmaceuticals leads this study, which shows 19 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Apr 2017 · 31 days · monthly snapshot~Apr 2017 – ~Jun 2017 · 2 months · monthly snapshot~Jun 2017 – ~Aug 2017 · 2 months · monthly snapshot~Aug 2017 – ~Sep 2017 · 31 days · monthly snapshot~Sep 2017 – ~Dec 2017 · 3 months · monthly snapshot~Dec 2017 – ~Jan 2018 · 31 days · monthly snapshot~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshot~Jun 2018 – ~Sep 2019 · 15 months · monthly snapshot~Sep 2019 – ~Feb 2020 · 5 months · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Jun 2020 · 3 months · monthly snapshot~Jun 2020 – ~Jan 2021 · 7 months · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Jul 2024 · 37 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

19 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE4

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE4

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  4. Jun 2021 — Jul 2024 [monthly]

    Completed PHASE4

  5. Jan 2021 — Jun 2021 [monthly]

    Completed PHASE4

▶ Show 14 earlier versions

  1. Jun 2020 — Jan 2021 [monthly]

    Completed PHASE4

    Status: Active Not Recruiting → Completed

  2. Mar 2020 — Jun 2020 [monthly]

    Active Not Recruiting PHASE4

  3. Feb 2020 — Mar 2020 [monthly]

    Active Not Recruiting PHASE4

  4. Sep 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE4

  5. Jun 2018 — Sep 2019 [monthly]

    Active Not Recruiting PHASE4

    Status: Recruiting → Active Not Recruiting

  6. Jan 2018 — Jun 2018 [monthly]

    Recruiting PHASE4

  7. Dec 2017 — Jan 2018 [monthly]

    Recruiting PHASE4

  8. Sep 2017 — Dec 2017 [monthly]

    Recruiting PHASE4

  9. Aug 2017 — Sep 2017 [monthly]

    Recruiting PHASE4

  10. Jun 2017 — Aug 2017 [monthly]

    Recruiting PHASE4

  11. Apr 2017 — Jun 2017 [monthly]

    Recruiting PHASE4

  12. Mar 2017 — Apr 2017 [monthly]

    Recruiting PHASE4

  13. Feb 2017 — Mar 2017 [monthly]

    Recruiting PHASE4

  14. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE4

    First recorded

Nov 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Regeneron Pharmaceuticals
  • Sanofi
Data source: Regeneron Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aguascalientes, Mexico , Ames, United States , Auburn, United States , Aurora, United States , Baltimore, United States , Bangor, United States , Beverly Hills, United States , Birmingham, United States , Bloemfontein, South Africa , Bristol, United States and 123 more locations